Highlights Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Delayed Nasdaq Other stock markets 14:06:35 2024-05-14 EDT			5-day change	1st Jan Change
2.88 ^USD	-8.57%		+1.41%	-14.03%

05-07	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	11-30	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	23-07-31	MT
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-28	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company	23-05-12	MT
J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.	23-05-10	CI
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment	23-04-03	MT
Cyclerion Therapeutics Says FDA Grants Orphan Drug Designation to Zagociguat; Shares Jump	23-03-27	MT
Cyclerion Therapeutics' Zagociguat Gets FDA Orphan Drug Status	23-03-23	MT
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
A group including Cyclerion Therapeutics, Inc.'s Chief Executive Officer cancelled the acquisition of Certain Assets of Cyclerion Therapeutics, Inc..	22-11-21	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia	22-07-28	CI
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation	22-06-28	CI
Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease	22-06-17	CI
Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 Symposium	22-06-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Highlights

Filters